Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies. Issue 42 (6th October 2022)
- Record Type:
- Journal Article
- Title:
- Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies. Issue 42 (6th October 2022)
- Main Title:
- Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies
- Authors:
- Yamanaka, Atsushi
Rattanaamnuaychai, Pimploy
Matsuda, Mami
Suzuki, Ryosuke
Matsuura, Yoshiharu
Tatsumi, Masashi
Konishi, Eiji - Abstract:
- Highlights: Flavivirus vaccines induce crossreactive neutralizing and enhancing antibodies. Genetically-manipulated DNA vaccines modified crossreactivity against flaviviruses. A manipulation of D87N increased in crossreactive neutralization to flaviviruses. The single amino acid substitution dramatically reduced crossreactive ADE activity. A genetic engineering contributes to develop safe and effective flavivirus vaccine. Abstract: Flaviviruses are important human pathogens because of their global distribution and disease severity. The high structural similarity among flaviviruses induces cross-immunity, with individual flaviviruses exhibiting crossreactive infection-enhancing and/or -neutralizing activities against other flaviviruses. Unlike neutralizing antibodies, enhancing antibodies may increase the risk of disease severity. Vaccine-induced enhancement remains a concern in the development of flavivirus vaccines. Here, we immunized mice with DNA vaccine candidates (pcJEME, pcWNME or pcZIKME) against Japanese encephalitis virus (JEV), West Nile virus (WNV) or Zika virus (ZIKV), respectively, and investigated crossreactive neutralizing and enhancing antibody activities against seven flaviviruses. pcZIKME induced higher cross-neutralization against dengue viruses than against JEV and WNV. Moreover, pcZIKME with a single amino acid substitution (D87N) showed an increase in crossreactive neutralizing activity and a decrease in enhancing activities against other flaviviruses.Highlights: Flavivirus vaccines induce crossreactive neutralizing and enhancing antibodies. Genetically-manipulated DNA vaccines modified crossreactivity against flaviviruses. A manipulation of D87N increased in crossreactive neutralization to flaviviruses. The single amino acid substitution dramatically reduced crossreactive ADE activity. A genetic engineering contributes to develop safe and effective flavivirus vaccine. Abstract: Flaviviruses are important human pathogens because of their global distribution and disease severity. The high structural similarity among flaviviruses induces cross-immunity, with individual flaviviruses exhibiting crossreactive infection-enhancing and/or -neutralizing activities against other flaviviruses. Unlike neutralizing antibodies, enhancing antibodies may increase the risk of disease severity. Vaccine-induced enhancement remains a concern in the development of flavivirus vaccines. Here, we immunized mice with DNA vaccine candidates (pcJEME, pcWNME or pcZIKME) against Japanese encephalitis virus (JEV), West Nile virus (WNV) or Zika virus (ZIKV), respectively, and investigated crossreactive neutralizing and enhancing antibody activities against seven flaviviruses. pcZIKME induced higher cross-neutralization against dengue viruses than against JEV and WNV. Moreover, pcZIKME with a single amino acid substitution (D87N) showed an increase in crossreactive neutralizing activity and a decrease in enhancing activities against other flaviviruses. A similar trend was observed in pcWNME. Engineered antigen might contribute to the development of safe and effective flavivirus vaccines. … (more)
- Is Part Of:
- Vaccine. Volume 40:Issue 42(2022)
- Journal:
- Vaccine
- Issue:
- Volume 40:Issue 42(2022)
- Issue Display:
- Volume 40, Issue 42 (2022)
- Year:
- 2022
- Volume:
- 40
- Issue:
- 42
- Issue Sort Value:
- 2022-0040-0042-0000
- Page Start:
- 6004
- Page End:
- 6011
- Publication Date:
- 2022-10-06
- Subjects:
- Flavivirus -- DNA vaccine -- Genetic manipulation -- Crossreactivity -- Neutralizing antibody -- Antibody-dependent enhancement
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2022.09.012 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23967.xml